INTEGRATED PATHWAY ANALYSIS OF SMALL CELL LUNG CANCER: NOTCH ALTERATIONS AS AN INDEPENDENT FAVORABLE PROGNOSTIC FACTOR AND DNA DAMAGE REPAIR ALTERATIONS AS CORRELATES OF TUMOR MUTATIONAL BURDEN

Elif Sertesen CAMOZ, Cengiz KARACIN

The Atlantic Journal of Medical Science and Research - 2026;6(3):377-386

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology, University of Health Sciences, Ankara, Türkiye

 

Aim: Small cell lung cancer (SCLC) is characterized by near-universal TP53/RB1 inactivation and high mutation burden, yet prognostic biomarkers beyond clinical stage remain limited. This study aimed to characterize pathway-level genomic alterations-including DNA damage repair (DDR), NOTCH, mismatch repair (MMR), and MYC family-and evaluate their associations with tumor mutational burden (TMB) and overall survival in a whole-genome sequenced SCLC cohort. Materials and Methods: We analyzed genomic and clinical data from 120 primary SCLC tumors in the University of Cologne cohort, accessed via cBioPortal. A 34-gene panel spanning homologous recombination, DNA damage signaling, Fanconi anemia, MMR, NOTCH (NOTCH1/2), cell cycle regulators (TP53, RB1), and MYC family genes was interrogated. Pathway co-occurrence was assessed using Fisher's exact tests. TMB comparisons used Mann-Whitney U tests. Overall survival was analyzed via Kaplan-Meier estimates, log-rank tests, and multivariable Cox proportional hazards regression adjusted for age, sex, tumor stage, and chemotherapy. Results: TP53 (85.8%) and RB1 (72.5%) alterations co-occurred strongly (odds ratio [OR] = 20.6, p < .001). DDR pathway alterations were present in 26.7% of tumors, with homologous recombination-altered cases showing markedly elevated TMB (median 12.6 vs 7.0, p = .001). NOTCH pathway alterations occurred in 16.7% of tumors. In multivariable Cox regression, NOTCH alterations were an independent favorable prognostic factor (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.24 - 0.94, p = .03) after adjustment for age, sex, advanced stage, and chemotherapy. DDR alterations did not independently predict survival (HR 1.14, p = .64). Advanced stage independently predicted worse survival (HR 2.38, p < .001), while chemotherapy was associated with better survival (HR 0.44, p = .001). Conclusion: In this SCLC cohort, NOTCH and DDR pathways demonstrate distinct biological roles: NOTCH alterations serve as an independent favorable prognostic marker, while DDR alterations associate with elevated TMB without independent prognostic impact. These findings validate NOTCH as a prognostic biomarker in SCLC and support pathway-level genomic assessment in clinical risk stratification.